Marina Biotech Receives Patent Acceptance Broadly Covering Its Unlocked Nucleobase Analog Technology
News Jan 23, 2012
The company has announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Companies, Inc., relating to the development and commercialization of the Company's ondansetron HCl oral spray product.
Pursuant to the agreements terminating the Talon and Par license agreements, all rights to develop and commercialize the product were returned to the Company in exchange for Talon's right to receive certain royalty payments in connection with the product. The Company believes the termination of these license agreements better positions the Company for a potential strategic transaction by returning control of the product within the United States and Canada to the Company. Further details regarding the terms of the termination agreements can be found in the Company's Current Report on Form 8-K filed in connection herewith.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.